Retraction Note to: Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer’s disease(Molecular Psychiatry, (2014), 19, (511–518), 10.1038/mp.2013.23);Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease

Molecular Psychiatry

Volumn 19, Issue 4, 2014, Pages 511-518

  Giannopoulos, P F ^a   Chu, J ^a   Joshi, Y B ^a   Sperow, M ^a   Li, J G ^a   Kirby, L G ^a   Pratico D ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 lipoxygenase; Alzheimer's disease; Amyloid beta; Memory; Synapse; Tau protein; Transgenic mouse models

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; IN VIVO STUDY; MALE; MEMORY; MOUSE; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN METABOLISM; SYNAPTIC DYSFUNCTION; SYNAPTIC POTENTIAL;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BRAIN; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; FEAR; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; SYNAPSES; TAU PROTEINS;

EID: 84897110156     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/s41380-022-01813-2     Document Type: Erratum

References (24)

1. Selkoe DJ. Alzheimer's disease, genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766
2. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 933-944
3. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 2011; 178: 2811-2822
4. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580
5. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421
6. Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007; 32: 332-341
7. Chinnici CM, Yao Y, Praticò D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging 2007; 28: 1457-1462
8. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST. Increased 5-lipooxygenase immunoreactivity in hippocampus of patients with Alzheimer' diseases. J Histochem Cytochem 2008; 56: 1065-1073
9. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Praticò D. 5-Lipoxygenase gene disruption reduces amyloid-b pathology in a mouse model of Alzheimer's disease. FASEB J 2008; 22: 1169-1178
10. Chu J, Praticò D. Pharmacological blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model. Am J Pathol 2011; 178: 1762-1769
11. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol 2012; 72: 1762-1769
12. Goulet JL, Snouwaert JN, Latourt AM, Coffman TM, Koller BH. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci 1994; 91: 12852-12856
13. Yang H, Zhuo J, Chu J, Chinnici C, Pratico D. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry 2010; 68: 922-929
14. Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould T, Pratico D. Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res 2010; 7: 140-149
15. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003; 86: 582-590
16. Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu Rev Physiol 2002; 64: 355-405
17. Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31-39
18. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease correlation with cognitive severity. Ann Neurol 1990; 27: 457-464
19. Scheff SW, Scott SA, DeKosky ST. Quantitation of synaptic density in the septal nuclei of young and aged Fischer 344 rats. Neurobiol Aging 1991; 12: 3-12
20. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995; 16: 285-304
21. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel Jr DW et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127-129
22. Hessler NA, Shirke AM, Malinow R. The probability of transmitter release at a mammalian central synapse. Nature 1993; 366: 569-572
23. Imbesi M, Zavoreo I, Uz T, Sharma RP, Dimitrijevic N, Manev H et al. 5-Lipoxygenase inhibitor MK-886 increases GluR1 phosphorylation in neuronal cultures in vitro and in the mouse cortex in vivo. Brain Res 2007; 1147: 148-153
24. Chen H, Manev H. Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice. Neuropharmacology 2011; 60: 1058-1063.